Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

(2013) E. Jourdan et al.   BLOOD

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease

(2013) Montserrat Hoyos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22)

(2013) Lixia Zhang et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

Prognostic Significance of Leukopenia at the Time of Diagnosis in Acute Myeloid Leukemia

(2011) Martha Arellano et al.   Clinical Lymphoma Myeloma & Leukemia

Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML

(2010) J. A. Pollard et al.   BLOOD

Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98

(2010) Christine von Neuhoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12

(2010) Christine J. Harrison et al.   JOURNAL OF CLINICAL ONCOLOGY

Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines

(2009) S Mallett et al.   BRITISH JOURNAL OF CANCER

Risk-Stratified Therapy and the Intensive Use of Cytarabine Improves the Outcome in Childhood Acute Myeloid Leukemia: The AML99 Trial From the Japanese Childhood AML Cooperative Study Group

(2009) Ichiro Tsukimoto et al.   JOURNAL OF CLINICAL ONCOLOGY

A ≥1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse

(2008) Steven Lane et al.   LEUKEMIA & LYMPHOMA